Table 2.

Number of COVID-19 vaccine candidates and platforms in the late stage pre-clinical and clinical phases.

Platform		Clinical	Preclinical
PS	Protein subunit	31	70
VVnr	Viral Vector (non-replicating)	16	21
DNA	DNA	10	16
IV	Inactivated Virus	16	9
RNA	RNA	16	24
VVr	Viral Vector (replicating)	5	19
VLP	Virus Like Particle	5	18
VVr + APC	VVr + Antigen Presenting Cell	2	-
LAV	Live Attenuated Virus	2	2
VVnr + APC	VVnr + Antigen Presenting Cell	1	-
LABV	Live attenuated bacterial vector	-	2
BVr	Bacterial vector (Replicating)	-	1